Eli Lilly pushes back timeline for Alzheimer’s drug application
By Leroy Leo (Reuters) – Eli Lilly and Co deferred its timeline to complete application for accelerated approval of its experimental Alzheimer’s drug, saying it expects such an approval to make little difference with Medicare’s limited coverage terms. Shares of Eli Lilly fell 2.6% to $244.21 on Thursday, after the drugmaker said it would complete …
Eli Lilly pushes back timeline for Alzheimer’s drug application Read More »










